Skip to content

Study Comparing MRI/Ultrasound Fusion-guided Prostate Biopsy Versus Systematic Transrectal Ultrasound-guided Biopsy

Prospective Multicenter, Randomized Study Comparing the Diagnostic Efficacy of a Targeted MRI/Ultrasound Fusion-guided Prostate Biopsy Versus a Systematic Transrectal Ultrasound-guided Biopsy in Men With at Least on Negative Prostate Biopsy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02450266
Acronym
PROFUSE
Enrollment
586
Registered
2015-05-21
Start date
2015-02-28
Completion date
2018-02-28
Last updated
2015-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

Primary disease, multiparametric MRI, targeted prostate biopsy, MRI/ultrasound fusion-guided prostate biopsy, systematic transrectal ultrasound-guided prostate biopsy

Brief summary

Patients will be submitted to a multiparametric MRI examination of the prostate. Subsequently, all participants will be randomized (1:1) into both study arms. In study arm A patients will be submitted to the gold-standard which comprises systematic transrectal ultrasound-guided prostate biopsy. In study arm B patients will be submitted to targeted prostate biopsy based on the multiparametric MRI findings.

Detailed description

In men with previously negative prostate biopsy and persistent elevated prostate-specific antigen (PSA) value, it is unclear which biopsy strategy offers the highest detection rate for significant prostate cancer. The hypothesis of this study is that targeted MRI/ultrasound fusion-guided biopsy improves the detection rates of significant prostate cancers compared with systematic transrectal ultrasound-guided prostate biopsy. Men with at least one previously negative transrectal ultrasound-guided biopsy and persistently elevated PSA values (\> 3 ng/ml) or PSA velocity \>0.75 ng/ml/p.a. will be submitted to a multiparametric MRI examination of the prostate. Subsequently, all participants will be randomized (1:1) into both study arms. In study arm A patients will be submitted to the gold-standard which comprises systematic transrectal ultrasound--guided prostate biopsy. In study arm B patients will be submitted to targeted prostate biopsy based on the multiparametric MRI findings. Targeted biopsies will be performed using MRI/ultrasound fusion-guided.

Interventions

DEVICESystematic transrectal ultrasound-guided prostate biopsy

12-18 systematic biopsy cores

DEVICEMRI/ultrasound fusion-guided prostate biopsy

2 targeted biopsy cores from each prostate lesion

Sponsors

German Cancer Research Center
CollaboratorOTHER
Heinrich-Heine University, Duesseldorf
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* At least one negative transrectal ultrasound-guided prostate biopsy * PSA \> 3.0 ng/ml or PSA velocity \>0.75 ng/ml/p.a.

Exclusion criteria

* Known prostate cancer * PSA \>50 ng/ml * Previous MRI-targeted prostate biopsy

Design outcomes

Primary

MeasureTime frame
Detection rate of significant prostate cancersOne week after biopsy

Secondary

MeasureTime frame
Overall detection rate of prostate cancersOne week after biopsy

Countries

Germany

Contacts

Primary ContactChristian Arsov, MD
christian.arsov@med.uni-duesseldorf.de+49 211 8108607

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026